Two paragraphs on page 1168 of Suzuki & Suzuki[@b1-opth-4-1277] were not cited correctly.

The data presented in the first paragraph should have been cited with reference number 35 and the following paragraph with a new reference, number 36. All subsequent references and citations were renumbered by one. The corrected text follows:

In another double-masked crossover trial, Konstas et al could not find any difference in 24-hour IOP measurements between adjunctive dorzolamide twice daily and brimonidine 0.15% twice daily in combination with latanoprost after six weeks of adjunctive therapy.^35^

In a single-arm, open-label study of brinzolamide ophthalmic suspension (1%) by Dr Franks for the Brinzolamide Study Group, the mean baseline IOP of the 79 patients was 22.5 (15--31) mmHg. Four weeks later, the mean IOP of the 78 patients under treatment with a combination of travoprost and brinzolamide was 18.5 (12--24) mmHg. Finally, 12 weeks later, the mean IOP for 71 evaluable patients was 18.2 (10--27) mmHg. At all time points, IOP was significantly reduced when compared with baseline values (*P* \< 0.0001). The average IOP had decreased by 3.9 mmHg (17.4%) after four (n = 78) and by 4.2 mmHg (18.4%) after 12 (n = 71) weeks of combined travoprost and brinzolamide therapy when compared with the monotherapy baseline of travoprost ophthalmic solution 0.004%. After four weeks of adjunctive treatment, 56% of patients (n = 78) and 63% of patients after 12 weeks (n = 71) had at least an additional 15% reduction in IOP.[@b36-opth-4-1277]
